Our 2020 volunteer award winners have been announced
Our recent survey has found that nearly three quarters (74%) of people on Parkinson's medication experience 'wearing off', when symptoms including pain, stiffness and tremors become worse between doses.
People with Parkinson’s are losing an average of two and a half hours a day to debilitating symptoms when their medication wears off, a Parkinson’s UK survey has found.
Parkinson’s UK is joining forces with US charity The Michael J. Fox Foundation and biopharma company Neurolixis to fund a £1.5m clinical trial of an exciting new drug to combat dyskinesia in people with Parkinson’s.
Find out about a parliamentary committee we gave evidence to about the impact of coronavirus on people with Parkinson’s
We're funding a new research study into a possible treatment for hallucinations in Parkinson's.
Researchers in the US have uncovered a link between long-term exposure to pollution and deterioration in health conditions. This includes Parkinson's and Alzheimer's.
Parkinson's UK funded research suggests it may be possible to prevent the formation of protein clumps that cause problems in Parkinson's by using microscopic tweezers that pull apart the proteins. This could pave the way for a therapy that could slow or stop the progression of the condition.
Sharing the results of the 'What Matters Most?' survey and coronavirus poll that have determined our campaigning priorities for the next four years
Simvastatin is a drug already used to lower cholesterol, and prevent heart attacks and strokes. Initial results from a major clinical trial show it doesn't have potential to slow the progression of Parkinson's as previously hoped.
Researchers in Portugal have discovered that the content of dreams, particularly those with negative emotions, may predict long-term cognitive decline in people with Parkinson’s.
An international team of researchers have uncovered a biological link that may account for why those with diabetes have a higher risk of developing Parkinson’s.
We’re investing a further £1 million to drive forward drugs that target energy-producing mitochondria to slow the loss of brain cells in Parkinson's.
Parkinson's UK has invested an additional £1 million in NRG Therapeutics Ltd’s mitochondrial drug development programme.
Parkinson’s UK chose to stay quiet during the recent Black Lives Matter conversations. We believed that by giving others space to have their voices heard, we were playing a role in supporting their message. We were wrong.
A US-based team has published results after treating one individual with an experimental stem cell therapy. The therapy involved surgically transplanting new brain cells, made from the patient's own skin, into the brain of a man with Parkinson's.
A team of researchers at the University of York have shown a protein called Rab10 plays an important role in the loss of brain cells in LRRK2-associated Parkinson’s.
Cannabis-based compounds could be the silver bullet to relieve pain for people with Parkinson’s according to the largest ever study into pain and the condition.